表紙
市場調査レポート

PharmaPoint:季節性インフルエンザワクチン - インドにおける医薬品の予測と市場分析

PharmaPoint: Seasonal Influenza Vaccines India Drug Forecast and Market Analysis

発行 GlobalData 商品コード 258672
出版日 ページ情報 英文 62 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
PharmaPoint:季節性インフルエンザワクチン - インドにおける医薬品の予測と市場分析 PharmaPoint: Seasonal Influenza Vaccines India Drug Forecast and Market Analysis
出版日: 2012年11月30日 ページ情報: 英文 62 Pages
概要

2012年におけるインドのインフルエンザワクチン市場は、およそ7100万米ドルとなりました。今後の市場成長は、幾多の市場障壁の影響により、大幅な拡大は見込めないでしょう。

当レポートでは、インドの季節性インフルエンザワクチン市場について調査し、市場の概要、競合情勢、主要薬剤の詳細情報とSWOT分析、主要薬剤の売上予測、主要イベントの影響分析、市場影響因子の分析などをまとめ、概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 疾病の概要

  • 病因・病態生理
    • 病因
    • 病態生理
  • 症状
  • 予後

第4章 疾病管理

  • インフルエンザ予防接種政策
  • インド
    • ンフルエンザ予防接種の推奨・政策
    • 臨床診療

第5章 競合評価

  • 概要
  • 戦略的競合評価
  • 製品プロファイル:主要ブランド

第6章 機会・アンメットニーズ

  • 概要
  • アンメットニーズ
    • 高い患者認識の水準
    • 高齢者・子供(2歳以下)における効能の向上
    • 改善したワクチン副作用のプロファイル
    • より効率的なワクチン製造プロセス
    • よりコスト効果的なワクチン
  • ギャップ分析
  • 機会
    • ウィルス株に対する防御幅の拡大
    • 防御持続期間の増加
    • T細胞の関与

第7章 パイプライン評価

  • 概要
  • 臨床開発中の有望薬剤

第8章 市場展望

  • インド
    • 予測
    • 主なイベント
    • 促進因子・阻害因子

第9章 付録

図表

目次
Product Code: GDHC1018CFR

Summary

GlobalData has released its new Country report, "PharmaPoint: Seasonal Influenza Vaccines India Drug Forecast and Market Analysis". Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as Sanofi's Fluzone and Vaxigrip, GlaxoSmithKline's Fluarix and FluLaval and Novartis' Fluvirin garner the majority stake of the market. However, with the entrance of vaccines with novel routes of administration, such as AstraZeneca's intranasal FluMist and Sanofi's Fluzone IntraDermal, GlobalData projects a dramatic shift favoring the adoption of such vaccines over the traditional intramuscular vaccines. GlobalData also anticipates that manufacturers that launch quadrivalent formulations will steal market share, patient share, and revenue from the trivalent influenza vaccines currently available.

The Indian influenza vaccine market is valued at $71 million for 2012. The market is forecast to grow slightly during the forecast period due to numerous market barriers overpowering any drivers of growth. Lack of a centralized healthcare policy regarding vaccination and limited awareness of the burden and threat of influenza among both Indian physicians and patients are examples of things hindering the growth of the influenza vaccine market in India.

Scope

  • Overview of seasonal influenza, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in India including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in India from 2012 to 2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting the India seasonal influenza market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for seasonal influenza
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012 to 2022 in India.

Table of contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms
  • 3.3. Prognosis

4. Disease Management

  • 4.1. Influenza Vaccination Policy
  • 4.2. India
    • 4.2.1. Influenza Vaccination Recommendations and Policies
    • 4.2.2. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment
  • 5.3. Product Profiles - Major Brands
    • 5.3.1. Fluarix/FluLaval
    • 5.3.2. Vaxigrip/Mutagrip
    • 5.3.3. Agrippal

6. Opportunity and Unmet Need

  • 6.1. Overview
  • 6.2. Unmet Needs
    • 6.2.1. Higher level of patient awareness
    • 6.2.2. Increased efficacy in the elderly and young children (<2 years old)
    • 6.2.3. Improved vaccine side-effect profiles
    • 6.2.4. More efficient vaccine manufacturing process
    • 6.2.5. More cost-effective vaccines
  • 6.3. Gap Analysis
  • 6.4. Opportunities
    • 6.4.1. Expanded breadth of protection against viral strains
    • 6.4.2. Increased duration of protection
    • 6.4.3. T-cell involvement

7. Pipeline Assessment

  • 7.1. Overview

8. Market Outlook

  • 8.1. India
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Vaccine Coverage
    • 9.4.2. Vaccines Included
    • 9.4.3. Key Launch Dates
    • 9.4.4. Influenza Vaccine Tender System Assumptions
    • 9.4.5. General Pricing Assumptions
    • 9.4.6. Individual Vaccine Assumptions
  • 9.5. Physicians and Specialists Included in this Study
  • 9.6. Primary Research - Prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Authors
    • 9.7.2. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Contact Us
  • 9.10. Disclaimer

List of Tables

  • Table 1: Notable Influenza Pandemics
  • Table 2: Symptoms of Influenza
  • Table 3: Leading Influenza Vaccines, 2012
  • Table 4: Product Profile - Fluarix
  • Table 5: Fluarix SWOT Analysis, 2012
  • Table 6: Product Profile - Vaxigrip
  • Table 7: Laboratory-Confirmed Influenza Infection Rates in Vaccine or Placebo Recipients and their Household Contacts
  • Table 8: Vaxigrip SWOT Analysis, 2012
  • Table 9: Product Profile - Agrippal
  • Table 10: Agrippal SWOT Analysis, 2012
  • Table 11: Overall Unmet Needs - Current Level of Attainment
  • Table 12: Clinical Unmet Needs - Gap Analysis, 2012
  • Table 13: Sales Forecasts ($m) for Influenza Vaccines in India, 2012-2022
  • Table 14: Key Events Impacting Sales of Influenza Vaccines in India, 2012
  • Table 15: Influenza Vaccine Market - Drivers and Barriers, 2012
  • Table 16: Key Launch Dates
  • Table 17: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Influenza Virus Structure
  • Figure 2: Sales for Influenza Vaccines in India by Route of Administration, 2012-2022
Back to Top